Date: 2017-01-09
Type of information: Collaboration agreement
Compound: selective orexin 1 antagonists
Company: Chronos Therapeutics (UK) Aptuit (USA - CT)
Therapeutic area: Addictive diseases - CNS diseases - Mental diseases
Type agreement: development - collaboration
Action mechanism: orexin 1 antagonist.
Disease: addictive behaviours of binge eating and alcohol use disorders
Details:
- • On January 9, 2017, Chronos Therapeutics, a private biotech company focused on ageing diseases, brain and nervous system disorders, announced that they have partnered with a subsidiary of Aptuit Holdings for services related to Chronos’ programme targeting the addictive behaviours of binge eating and alcohol use disorders.
- The companies will work together on integrated drug discovery (medicinal and computational chemistry, biology and DMPK) to optimise Chronos’ selective orexin 1 antagonists that have shown considerable promise in treating addiction. Chronos will lead the programme and have access to world leading experts at the Aptuit site in Verona, Italy. All intellectual property, know-how, development and marketing rights for the programme will belong to Chronos. Each of the addictive behaviours targeted represents an area of significant unmet medical need, complementing Chronos’ additional programmes for the fatal neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) and fatigue associated with multiple sclerosis (MS).
Financial terms:
Latest news:
Is general: Yes
